BROOKPHARM LIMITED

Company Registration Number:
04751759 (England and Wales)

Unaudited abridged accounts for the year ended 26 May 2024

Period of accounts

Start date: 01 June 2023

End date: 26 May 2024

BROOKPHARM LIMITED

Contents of the Financial Statements

for the Period Ended 26 May 2024

Balance sheet
Notes

BROOKPHARM LIMITED

Balance sheet

As at 26 May 2024


Notes

2024

2023


£

£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets: 3 330,000 360,000
Tangible assets: 4 1,628 2,589
Total fixed assets: 331,628 362,589
Current assets
Stocks: 35,329 16,480
Debtors: 5 1,625,123 2,333,789
Cash at bank and in hand: 1,396,504 588,002
Total current assets: 3,056,956 2,938,271
Creditors: amounts falling due within one year: 6 (268,800) (331,571)
Net current assets (liabilities): 2,788,156 2,606,700
Total assets less current liabilities: 3,119,784 2,969,289
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: 0 0
Total net assets (liabilities): 3,119,784 2,969,289
Capital and reserves
Called up share capital: 100 100
Profit and loss account: 3,119,684 2,969,189
Shareholders funds: 3,119,784 2,969,289

The notes form part of these financial statements

BROOKPHARM LIMITED

Balance sheet statements

For the year ending 26 May 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 25 February 2025
and signed on behalf of the board by:

Name: Jaent Kumar Phakkey
Status: Director

The notes form part of these financial statements

BROOKPHARM LIMITED

Notes to the Financial Statements

for the Period Ended 26 May 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Tangible fixed assets and depreciation policy

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows: Fittings fixtures and equipment - 15% reducing balance Motor vehicles - 20% reducing balance If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Intangible fixed assets and amortisation policy

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows: If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Valuation and information policy

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Other accounting policies

Financial instruments The company holds only basic financial instruments such as cash, debtors and creditors, for which carrying amount is equivalent to fair value. Defined contribution plans Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises. Cash and cash equivalents Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. Trade debtors Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables. Trade creditors Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

BROOKPHARM LIMITED

Notes to the Financial Statements

for the Period Ended 26 May 2024

2. Employees

2024 2023
Average number of employees during the period 4 4

BROOKPHARM LIMITED

Notes to the Financial Statements

for the Period Ended 26 May 2024

3. Intangible Assets

Total
Cost £
At 01 June 2023 600,000
Additions 0
Disposals 0
Revaluations 0
Transfers 0
At 26 May 2024 600,000
Amortisation
At 01 June 2023 240,000
Charge for year 30,000
On disposals 0
Other adjustments 0
At 26 May 2024 270,000
Net book value
At 26 May 2024 330,000
At 31 May 2023 360,000

BROOKPHARM LIMITED

Notes to the Financial Statements

for the Period Ended 26 May 2024

4. Tangible Assets

Total
Cost £
At 01 June 2023 17,504
Disposals (9,803)
At 26 May 2024 7,701
Depreciation
At 01 June 2023 14,915
Charge for year 287
On disposals (9,129)
At 26 May 2024 6,073
Net book value
At 26 May 2024 1,628
At 31 May 2023 2,589

BROOKPHARM LIMITED

Notes to the Financial Statements

for the Period Ended 26 May 2024

5. Debtors

2024 2023
££
Debtors due after more than one year: 0 0

BROOKPHARM LIMITED

Notes to the Financial Statements

for the Period Ended 26 May 2024

6. Creditors: amounts falling due within one year note

Trade Creditors 104,250 Corporation Tax 129,139 Social Security and other taxes 238 Other Creditors 35,173